Indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Alpha-2 adrenergic agonist: Anti-glaucoma
Brimonidine is an α-2 adrenoreceptor agonist that is more selective for the α-2 adrenoreceptor than α-1. Topical administration of Brimonidine Tartrate eye drops decreases intraocular pressure (IOP) in humans. When used as directed Brimonidine Tartrate have the action of reducing elevated IOP with minimal effect on cardiovascular parametres. Brimonidine Tartrate eye drops have a rapid onset of action with the peak ocular hypotensive effect occurring at two hours post-dosing. The duration of effect is 12 hours or greater. Fluorophotometric studies in animals and humans suggest that Brimonidine Tartrate has a dual mechanism of action. Brimonidine Tartrate eye drops lower IOP by reducing aqueous humor production and enhancing uveoscleral outflow.
OPHTHALMIC Open-angle glaucoma: Adult: Instill 1 drop of a 0.2% soln bid-tid.
Although specific drug interaction studies have not been conducted with Brimonidine Tartrate ophthalmic solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, or anesthetics) should be considered. Alpha-agonists, as a class, may reduce pulse and blood pressure. Caution in using concomitant drugs such as beta-blockers (ophthalmic and systemic), antihypertensives and/or cardiac glycosides is advised. Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic clonidine. It is not known whether the concurrent use of these agents with Brimonidine Tartrate ophthalmic solution in humans can lead to resulting interference with the IOP lowering effect. No data on the level of circulating catecholamines after administration of Brimonidine Tartrate ophthalmic solution are available. Caution, however, is advised in patients taking Tricyclic antidepressants which can affect the metabolism and uptake of circulating amines.
Hypersensitivity. Patients receiving MAO inhibitor therapy. Patients wearing soft contact lenses should wait for at least 15 min after instilling brimonidine tartrate before inserting soft contact lenses. Renal or hepatic impairment. CV disease. Use w/ caution in patients w/ depression, cerebral or coronary insufficiency. Raynaud’s phenomenon, orthostatic hypotension or thromboangitis obliterans. Pregnancy, lactation.
Oral dryness; ocular hyperaemia, burning & stinging; headache, blurring of vision; foreign body sensation, fatigue or drowsiness: conjunctival follicles, ocular allergic reactions & ocular pruritus. Corneal staining or erosion, photophobia, eyelid erythema. ocular ache & pain, ocular dryness, tearing; upper resp symptoms; eyelid oedema, conjunctival oedema, dizziness. blepharitis, ocular irritation; GI symptoms; asthaenia; conjunctival blanching, abnormal vision & muscular pain.
This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus. Use is not recommended during breastfeeding.
Store below 30°C in a cool and dry place protected from light. Keep out of reach of children. Do not touch the dropper tip to surfaces since this may contaminate the solution. Do not use after 30 days of first opening.
.png&w=384&q=75)